Achieving Hands-On Learning in Distance-Learning Environments

 

If there’s anyone qualified to speak to the strategies that work best for students in remote and virtual learning scenarios, it’s Micah Copeland, Elementary Principal at North Carolina Cyber Academy.

The Academy’s mission is to “empower children with knowledge, skills and character traits to be successful in their education through an engaging, personalized learning experience in a full-time virtual school.”

That means, when the COVID-19 pandemic forced the entire world to go remote, the NCCA was better prepared than most educational institutions. Now, even with reopening in full swing, Copeland offered insights into how educators can navigate the continuation of remote and hybrid learning environments and continue to deliver impactful, personalized experiences through these digital channels.

The biggest cornerstone to any successful virtual education strategy, Copeland said, is a simple one – you have to work to forge the same kinds of genuine relationships you would in a face-to-face setting.

“We really work to try to get to know our kids,” Copeland said. “That is important for us. Just like in the classroom, relationships are critical.”

The Academy has whole-group sessions, as well as targeted, one-on-one sessions that educators use to provide additional support. That combination of synchronous and asynchronous learning brings the best of both worlds to the school’s students.

To hear the entirety of Copeland’s insights into navigating the current educational landscape, listen to the entire conversation.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More